MedTrace Logo

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

NCT01135511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2013-05-07

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, low dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, high dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops-vehicle

Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks

DRUG

Sodium Hyaluronate

Ophthalmic topical solution, dosed 6 times/day, 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01135511 on ClinicalTrials.gov